Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2007

View Archived Issues

Sirtex initiates clinical trial of SIR-Spheres microspheres for hepatocellular carcinoma

FDA advisory panel recommends continued availability of rosiglitazone to U.S. patients, citing risks

Theregen begins second phase I trial of Anginera patch for heart failure

Differences in seroconversion not statistically significant in Ushercell HIV studies

New analgesic agents disclosed in recent patent literature

New drugs for immunological disorders divulged in recent Japanese patents

Alcon's Travatanz approved in Japan for glaucoma and ocular hypertension

Shire announces results for the second quarter 2007

Update on Fresenius' phase II/III study of removab for malignant ascites

Positive top-line results for Orexigen's phase IIb Empatic trial for obesity

Eslax, Organon's neuromuscular blocking agent, approved in Japan

Recent patent literature discloses new antidiabetic agents

Tysabri recommended for approval in the U.S. for moderate to severe Crohn's disease

Lev Pharmaceuticals seeks FDA approval for Cinryze for the acute treatment of HAE

Recent patent claims series of compounds for the treatment of urinary incontincence

Phase II trial of single-dose, oral Ty-800 typhoid vaccine begins

Meda and Recordati expand lercanidipine/enalapril collaboration

Qiagen acquisition of Digene completed

Neurocrine enters valnoctamide stereoisomers licensing agreement with Yissum

CMD defers marketing authorization decision of Oracea to CHMP

Intercept first to enter clinic with FXR modulator / News in Context

Brazilian researchers describe novel antiretroviral compound at IAS 2007

Live, attenuated SARS vaccine provides protection against lung infection in hamsters

Preclinical and clinical findings on first-in-class HIV maturation inhibitor discussed in Sydney

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...